Gland Pharma gets EIR from USFDA for Pashamylaram facility

18 Jan 2025 Evaluate

Gland Pharma has received Establishment Inspection Report (EIR) from the USFDA for its Pashamylaram facility at Hyderabad. USFDA has conducted inspection for Good Manufacturing Practices (GMP) at said facility between July 25, 2024 and August 02, 2024. The said inspection was concluded with three 483 Observations. 

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1524.25 3.85 (0.25%)
21-Feb-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1643.05
Dr. Reddys Lab 1151.95
Cipla 1474.30
Lupin 1906.15
Zydus Lifesciences 885.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on